Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 379

1.

Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.

Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, Cid MC, Dahlsveen K, de Zoysa J, Espigol-Frigolé G, Lanyon P, Peh CA, Tesar V, Vaglio A, Walsh M, Walsh D, Walters G, Harper L, Jayne D; European Vasculitis Study Group (EUVAS).

Ann Rheum Dis. 2019 Jan 5. pii: annrheumdis-2018-214245. doi: 10.1136/annrheumdis-2018-214245. [Epub ahead of print]

PMID:
30612116
2.

Predictors of Renal Outcomes in Sclerotic Class Anti-Neutrophil Cytoplasmic Antibody Glomerulonephritis.

Menez S, Hruskova Z, Scott J, Cormican S, Chen M, Salama AD, Alasfar S, Little MA, Safrankova H, Honsova E, Tesar V, Geetha D.

Am J Nephrol. 2018;48(6):465-471. doi: 10.1159/000494840. Epub 2018 Nov 23.

PMID:
30472700
3.

Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update.

Coppo R, D'Arrigo G, Tripepi G, Russo ML, Roberts ISD, Bellur S, Cattran D, Cook TH, Feehally J, Tesar V, Maixnerova D, Peruzzi L, Amore A, Lundberg S, Di Palma AM, Gesualdo L, Emma F, Rollino C, Praga M, Biancone L, Pani A, Feriozzi S, Polci R, Barratt J, Del Vecchio L, Locatelli F, Pierucci A, Caliskan Y, Perkowska-Ptasinska A, Durlik M, Moggia E, Ballarin JC, Wetzels JFM, Goumenos D, Papasotiriou M, Galesic K, Toric L, Papagianni A, Stangou M, Benozzi L, Cusinato S, Berg U, Topaloglu R, Maggio M, Ots-Rosenberg M, D'Amico M, Geddes C, Balafa O, Quaglia M, Cravero R, Lino Cirami C, Fellstrom B, Floege J, Egido J, Mallamaci F, Zoccali C.

Nephrol Dial Transplant. 2018 Nov 9. doi: 10.1093/ndt/gfy302. [Epub ahead of print]

PMID:
30418652
4.

Assessment of renal function before contrast media injection: right decisions based on inaccurate estimates.

Ptáčník V, Zogala D, Skibová D, Jiskrová H, Trnka J, Tesař V, Ryšavá R, Šámal M.

Eur Radiol. 2018 Nov 9. doi: 10.1007/s00330-018-5753-z. [Epub ahead of print]

PMID:
30413953
5.

DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.

Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Derebail VK, Gambaro G, Gesualdo L, Gipson DS, Hogan J, Lieberman K, Marder B, Meyers KE, Mustafa E, Radhakrishnan J, Srivastava T, Stepanians M, Tesar V, Zhdanova O, Komers R; DUET Study Group.

J Am Soc Nephrol. 2018 Nov;29(11):2745-2754. doi: 10.1681/ASN.2018010091.

PMID:
30361325
6.

Establishing Surrogate Kidney Endpoints for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes.

Mackay M, Dall'Era M, Fishbein J, Kalunian K, Lesser M, Sanchez Guerrero J, Levy DM, Silverman E, Petri M, Arriens C, Lewis EJ, Korbet SM, Conti F, Tesar V, Hruskova Z, Borba EF, Bonfa E, Chan TM, Rathi M, Gupta KL, Jha V, Hasni S, West MR, Silverman E, Solomons N, Houssiau FA, Romera Diaz J, Mejia-Vilet J, Rovin BH.

Arthritis Rheumatol. 2018 Sep 17. doi: 10.1002/art.40724. [Epub ahead of print]

PMID:
30225865
7.

Serum hepcidin is increased in ANCA-associated vasculitis and correlates with activity markers.

Přikryl P, Hrušková Z, Konopásek P, Hladinová Z, Tesař V, Vokurka M.

Physiol Res. 2018 Dec 18;67(6):945-954. Epub 2018 Sep 11.

8.

Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Geetha D, Jin Q, Scott J, Hruskova Z, Hanouneh M, Little MA, Tesar V, Seo P, Jayne D, Pagnoux C.

Kidney Int Rep. 2018 May 24;3(5):1039-1049. doi: 10.1016/j.ekir.2018.05.007. eCollection 2018 Sep. Review.

9.

Mutational screening of inverted formin 2 in adult-onset focal segmental glomerulosclerosis or minimal change patients from the Czech Republic.

Safarikova M, Stekrova J, Honsova E, Horinova V, Tesar V, Reiterova J.

BMC Med Genet. 2018 Aug 20;19(1):147. doi: 10.1186/s12881-018-0667-9.

10.

Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry.

Hruskova Z, Pippias M, Stel VS, Abad-Díez JM, Benítez Sánchez M, Caskey FJ, Collart F, De Meester J, Finne P, Heaf JG, Magaz A, Palsson R, Reisæter AV, Salama AD, Segelmark M, Traynor JP, Massy ZA, Jager KJ, Tesar V.

Am J Kidney Dis. 2018 Aug 16. pii: S0272-6386(18)30768-6. doi: 10.1053/j.ajkd.2018.05.016. [Epub ahead of print]

PMID:
30122544
11.

Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus.

Hruskova Z, Tesar V.

Expert Opin Biol Ther. 2018 Sep;18(9):989-996. doi: 10.1080/14712598.2018.1504918. Epub 2018 Jul 31.

PMID:
30040494
12.

Bilineal inheritance of pathogenic PKD1 and PKD2 variants in a Czech family with autosomal dominant polycystic kidney disease - a case report.

Elisakova V, Merta M, Reiterova J, Baxova A, Kotlas J, Hirschfeldova K, Obeidova L, Tesar V, Stekrova J.

BMC Nephrol. 2018 Jul 4;19(1):163. doi: 10.1186/s12882-018-0978-2.

13.

Avacopan in the treatment of ANCA-associated vasculitis.

Tesar V, Hruskova Z.

Expert Opin Investig Drugs. 2018 May;27(5):491-496. doi: 10.1080/13543784.2018.1472234. Epub 2018 May 8. Review.

PMID:
29718732
14.

Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.

Weiner M, Bjørneklett R, Hrušková Z, Mackinnon B, Poulton CJ, Sindelar L, Mohammad AJ, Eriksson P, Gesualdo L, Geetha D, Crnogorac M, Jayne D, Hogan SL, Geddes C, Tesar V, Aasarød K, Segelmark M.

Nephrol Dial Transplant. 2018 Apr 30. doi: 10.1093/ndt/gfy106. [Epub ahead of print]

PMID:
29718465
15.

Defective gene expression of the membrane complement inhibitor CD46 in patients with progressive immunoglobulin A nephropathy.

Coppo R, Peruzzi L, Loiacono E, Bergallo M, Krutova A, Russo ML, Cocchi E, Amore A, Lundberg S, Maixnerova D, Tesar V, Perkowska-Ptasinska A, Durlik M, Goumenos D, Gerolymos M, Galesic K, Toric L, Papagianni A, Stangou M, Mizerska-Wasia Membek M, Gesualdo L, Montemurno E, Benozzi L, Cusinato S, Hryszko T, Klinger M, Kaminska D, Krajewska M; VALIGA Study Group of the ERA-EDTA Immunonephrology Working Group.

Nephrol Dial Transplant. 2018 Apr 9. doi: 10.1093/ndt/gfy064. [Epub ahead of print]

PMID:
29635535
16.

Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease.

Čertíková Chábová V, Kujal P, Škaroupková P, Varňourková Z, Vacková Š, Husková Z, Kikerlová S, Sadowski J, Kompanowska-Jezierska E, Baranowska I, Hwang SH, Hammock BD, Imig JD, Tesař V, Červenka L.

Kidney Blood Press Res. 2018;43(2):329-349. doi: 10.1159/000487902. Epub 2018 Mar 6.

17.

Management of Elderly Patients with Rapidly Progressive Glomerulonephritis.

Hruskova Z, Tesar V.

Blood Purif. 2018;45(1-3):213-217. doi: 10.1159/000485368. Epub 2018 Jan 26.

18.

Molecular profiling in IgA nephropathy and focal and segmental glomerulosclerosis.

Tycová I, Hrubá P, Maixnerová D, Girmanová E, Mrázová P, Straňavová L, Zachoval R, Merta M, Slatinská J, Kollár M, Honsová E, Tesař V, Viklický O.

Physiol Res. 2018 Mar 16;67(1):93-105. Epub 2017 Nov 10.

19.

[Gliflozins slow down the progression of diabetic kidney disease].

Tesař V, Vachek J.

Vnitr Lek. Fall 2017;63(10):723-727. Review. Czech.

PMID:
29127757
20.

Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts.

Yates M, Watts R, Bajema I, Cid M, Crestani B, Hauser T, Hellmich B, Holle J, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel P, Mills J, Mooney J, Segelmark M, Tesar V, Westman KWA, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C.

RMD Open. 2017 Jun 15;3(1):e000449. doi: 10.1136/rmdopen-2017-000449. eCollection 2017.

21.

Pregnancy-Associated Plasma Protein A2 in Hemodialysis Patients: Significance for Prognosis.

Kalousová M, Dusilová-Sulková S, Kuběna AA, Zakiyanov O, Levová K, Bocková M, Gedeonová E, Song XC, Ermini ML, Špringer T, Homola J, Tesař V, Zima T.

Kidney Blood Press Res. 2017;42(3):509-518. doi: 10.1159/000479847. Epub 2017 Aug 30.

22.

Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease.

Tesar V, Ciechanowski K, Pei Y, Barash I, Shannon M, Li R, Williams JH, Levisetti M, Arkin S, Serra A.

J Am Soc Nephrol. 2017 Nov;28(11):3404-3413. doi: 10.1681/ASN.2016111232. Epub 2017 Aug 24.

23.

Immunosuppressive Treatment in C3 Glomerulopathy: Time to Reconsider Our Approach.

Tesar V, Hruskova Z.

Am J Nephrol. 2017;46(2):93-95. doi: 10.1159/000479014. Epub 2017 Jul 13. No abstract available.

24.

Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients.

McAdoo SP, Tanna A, Hrušková Z, Holm L, Weiner M, Arulkumaran N, Kang A, Satrapová V, Levy J, Ohlsson S, Tesar V, Segelmark M, Pusey CD.

Kidney Int. 2017 Sep;92(3):693-702. doi: 10.1016/j.kint.2017.03.014. Epub 2017 May 12.

25.

Understanding Histolopathologic Characteristics to Predict Renal Outcomes in Lupus Nephritis.

Tesar V, Hruskova Z.

Clin J Am Soc Nephrol. 2017 May 8;12(5):711-712. doi: 10.2215/CJN.03490317. Epub 2017 May 4. No abstract available.

26.

Belimumab in the management of systemic lupus erythematosus - an update.

Tesar V, Hruskova Z.

Expert Opin Biol Ther. 2017 Jul;17(7):901-908. doi: 10.1080/14712598.2017.1324846. Epub 2017 May 16. Review.

PMID:
28460578
27.

Proteomic approach for identification of IgA nephropathy-related biomarkers in urine.

Prikryl P, Vojtova L, Maixnerova D, Vokurka M, Neprasova M, Zima T, Tesar V.

Physiol Res. 2017 Sep 22;66(4):621-632. Epub 2017 Apr 12.

28.

Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.

Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, Burst V, Grundmann F, Jadoul M, Szombati I, Tesař V, Segelmark M, Potarca A, Schall TJ, Bekker P; CLEAR Study Group.

J Am Soc Nephrol. 2017 Sep;28(9):2756-2767. doi: 10.1681/ASN.2016111179. Epub 2017 Apr 11.

29.

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.

Fellström BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sørensen SS, Tesar V, Del Vecchio L; NEFIGAN Trial Investigators.

Lancet. 2017 May 27;389(10084):2117-2127. doi: 10.1016/S0140-6736(17)30550-0. Epub 2017 Mar 28.

PMID:
28363480
30.

[Current options of treatment of hyponatremia].

Tesař V.

Vnitr Lek. 2016 Winter;62 Suppl 6:97-101. Czech.

PMID:
28124939
31.

[Gitelman´s syndrome as common cause of hypokalemia and hypomagnesemia].

Ryšavá R, Reiterová J, Urbanová M, Štekrová J, Lněnička P, Tesař V.

Vnitr Lek. 2016 Winter;62 Suppl 6:78-83. Czech.

PMID:
28124936
32.

[Theralite and multiple myeloma].

Lachmanová J, Tesař V, Ryšavá R, Bartková M.

Vnitr Lek. 2016 Winter;62 Suppl 6:9-13. Czech.

PMID:
28124926
33.

Tissue ischemia worsens during hemodialysis in end-stage renal disease patients.

Malik J, Kudlicka J, Lachmanova J, Valerianova A, Rocinova K, Bartkova M, Tesar V.

J Vasc Access. 2017 Jan 18;18(1):47-51. doi: 10.5301/jva.5000630. Epub 2016 Nov 22.

PMID:
27886367
34.

NETosis provides the link between activation of neutrophils on hemodialysis membrane and comorbidities in dialyzed patients.

Korabecna M, Tesar V.

Inflamm Res. 2017 May;66(5):369-378. doi: 10.1007/s00011-016-1010-6. Epub 2016 Nov 24. Review.

35.

Toward Noninvasive Diagnosis of IgA Nephropathy: A Pilot Urinary Metabolomic and Proteomic Study.

Neprasova M, Maixnerova D, Novak J, Reily C, Julian BA, Boron J, Novotny P, Suchanek M, Tesar V, Kacer P.

Dis Markers. 2016;2016:3650909. Epub 2016 Oct 9.

36.

Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis.

Alberici F, Smith RM, Fonseca M, Willcocks LC, Jones RB, Holle JU, Wieczorek S, Neumann T, Martorana D, Gregorini G, Sinico RA, Bruchfeld A, Gunnarsson I, Ohlsson S, Baslund B, Tesar V, Hruskova Z, Cid MC, Vaglio A, Lyons PA, Smith KGC, Jayne DRW.

J Allergy Clin Immunol. 2017 May;139(5):1684-1687.e10. doi: 10.1016/j.jaci.2016.08.051. Epub 2016 Oct 22. No abstract available.

PMID:
27780742
37.

Erratum to: Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort.

Coppo R, Lofaro D, Camilla RR, Bellur S, Cattran D, Cook HT, Roberts IS, Peruzzi L, Amore A, Emma F, Fuiano L, Berg U, Topaloglu R, Bilginer Y, Gesualdo L, Polci R, Mizerska-Wasiak M, Caliskan Y, Lundberg S, Cancarini G, Geddes C, Wetzels J, Wiecek A, Durlik M, Cusinato S, Rollino C, Maggio M, Praga M, Smerud HK, Tesar V, Maixnerova D, Barratt J, Papalia T, Bonofiglio R, Mazzucco G, Giannakakis C, Soderberg M, Orhan D, Di Palma AM, Maldyk J, Ozluk Y, Sudelin B, Tardanico R, Kipgen D, Steenbergen E, Karkoszka H, Perkowska-Ptasinska A, Ferrario F, Gutierrez E, Honsova E.

Pediatr Nephrol. 2017 Jan;32(1):193-194. No abstract available.

38.

Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort.

Coppo R, Lofaro D, Camilla RR, Bellur S, Cattran D, Cook HT, Roberts IS, Peruzzi L, Amore A, Emma F, Fuiano L, Berg U, Topaloglu R, Bilginer Y, Gesualdo L, Polci R, Mizerska-Wasiak M, Caliskan Y, Lundberg S, Cancarini G, Geddes C, Wetzels J, Wiecek A, Durlik M, Cusinato S, Rollino C, Maggio M, Praga M, K Smerud H, Tesar V, Maixnerova D, Barratt J, Papalia T, Bonofiglio R, Mazzucco G, Giannakakis C, Soderberg M, Orhan D, Di Palma AM, Maldyk J, Ozluk Y, Sudelin B, Tardanico R, Kipgen D, Steenbergen E, Karkoszka H, Perkowska-Ptasinska A, Ferrario F, Gutierrez E, Honsova E.

Pediatr Nephrol. 2017 Jan;32(1):139-150. Epub 2016 Aug 25. Erratum in: Pediatr Nephrol. 2017 Jan;32(1):193-194.

39.

Lupus Nephritis: A Different Disease in European Patients?

Tesar V, Hruskova Z.

Kidney Dis (Basel). 2015 Sep;1(2):110-8. doi: 10.1159/000438844. Epub 2015 Aug 28. Review.

40.

Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study.

Frausová D, Hrušková Z, Lánská V, Lachmanová J, Tesař V.

Arthritis Res Ther. 2016 Jul 13;18:168. doi: 10.1186/s13075-016-1055-5.

41.

Urine sCD163: a window onto glomerular inflammation.

Møller HJ, Tesar V, Little MA.

Nephrol Dial Transplant. 2016 Dec;31(12):1970-1972. Epub 2016 Jun 29. No abstract available.

PMID:
27358273
42.

Left Atrial Dysfunction in End-Stage Renal Disease Patients Treated by Hemodialysis.

Malik J, Lachmanova J, Kudlicka J, Rocinova K, Valerianova A, Bartkova M, Tesar V.

Nephron. 2016;133(3):169-74. doi: 10.1159/000447500. Epub 2016 Jun 25.

PMID:
27344674
43.

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.

Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C.

Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133. Epub 2016 Jun 23.

44.

Moderator's view: Cyclophosphamide in lupus nephritis.

Tesar V.

Nephrol Dial Transplant. 2016 Jul;31(7):1058-61. doi: 10.1093/ndt/gfw067. Epub 2016 May 14.

PMID:
27190357
45.

Renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies.

Fiorentino M, Bolignano D, Tesar V, Pisano A, Biesen WV, Tripepi G, D'Arrigo G, Gesualdo L; ERA-EDTA Immunonephrology Working Group.

Nephrol Dial Transplant. 2017 Jan 1;32(1):97-110. doi: 10.1093/ndt/gfw070.

PMID:
27190327
46.

Markers for the progression of IgA nephropathy.

Maixnerova D, Reily C, Bian Q, Neprasova M, Novak J, Tesar V.

J Nephrol. 2016 Aug;29(4):535-41. doi: 10.1007/s40620-016-0299-0. Epub 2016 May 3. Review.

47.

Genome-wide methylation analysis of tubulocystic and papillary renal cell carcinomas.

Korabecna M, Geryk J, Hora M, Steiner P, Seda O, Tesar V.

Neoplasma. 2016;63(3):402-10. doi: 10.4149/309_151102N559.

PMID:
26925785
48.

HMGB1, S100 proteins and other RAGE ligands in cancer - markers, mediators and putative therapeutic targets.

Tesarova P, Kalousova M, Zima T, Tesar V.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Mar;160(1):1-10. doi: 10.5507/bp.2016.003. Epub 2016 Feb 3. Review.

49.

Renal Biopsy in 2015--From Epidemiology to Evidence-Based Indications.

Fiorentino M, Bolignano D, Tesar V, Pisano A, Van Biesen W, D'Arrigo G, Tripepi G, Gesualdo L; ERA-EDTA Immunonephrology Working Group.

Am J Nephrol. 2016;43(1):1-19. doi: 10.1159/000444026. Epub 2016 Feb 5. Review.

50.

Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up.

Pesickova SS, Rysava R, Lenicek M, Vitek L, Potlukova E, Hruskova Z, Jancova E, Honsova E, Zavada J, Trendelenburg M, Tesar V.

Arthritis Res Ther. 2015 Dec 24;17:371. doi: 10.1186/s13075-015-0879-8.

Supplemental Content

Support Center